ACADIA's Rising Revenue Story Meets A Battered Stock As Nuplazid's Second-Half Ramp Faces Its Test

ACADIA Pharmaceuticals heads into its third-quarter report with a striking disconnect. Three months ago management raised its full-year outlook, celebrated a reversal in Europe and described Daybue Stix adoption running ahead of plan. Since then the stock has fallen about 29%, trailing the S&P 500 by roughly 28 percentage points. The November 4 release, due after the close, has to show whether the commercial momentum is real enough to matter while the market weighs the remlifanserin readout that management had pegged for September or October.

The Street is looking for revenue of about $334.9 million, up 20.2% from $278.6 million a year ago and a solid step up from last quarter's $308.0 million. Earnings are expected at $0.21 per share, down 19.2% from $0.26, reflecting heavier spending on two expanded sales forces and marketing rather than any weakness at the top line. Management's revenue range of $1.24 billion to $1.30 billion compares with a consensus of $1.24 billion, which sits right at the floor. With first-half sales of roughly $576 million, that full-year figure implies fourth-quarter revenue slightly below the third-quarter estimate, even though management expects the German launch early in the fourth quarter and a back-half-weighted Nuplazid ramp. Either analysts are leaving room for upside or they doubt the guidance midpoint, and this report should help settle which.

Nuplazid is the bigger swing factor. Guidance of $760 million to $790 million was only reaffirmed last quarter, and with $350 million booked in the first half, the drug needs roughly $205 million to $220 million per quarter for the rest of the year, well above the $183 million recorded in the second quarter. Management cautioned that the 30% field-force expansion takes six to nine months to mature and that the third quarter would likely be softer than the fourth. A print that moves meaningfully toward $200 million, with volume growth improving on the 8% seen last quarter, would validate that story. Another quarter near 10% growth would make the low end of the range look more likely and put the roughly $1 billion 2028 ambition under more scrutiny.

Daybue carries the momentum. Sales rose 30% to $125 million last quarter, accelerating for a third straight period, and guidance was lifted to $480 million to $510 million. That range needs about $127 million to $142 million per quarter in the second half, so simply holding steady would not be enough to reach the midpoint. Useful evidence would include Stix moving beyond the roughly 40% share of U.S. patients reached by June, returning patients continuing to come back, and gross-to-net staying inside the newly raised 23% to 25% band. Early commentary on German pricing and uptake will also show whether Europe can become a real growth leg.

Expectations are mixed. Sentiment has improved noticeably to 45.8% bullish from 21.2% before the prior report, yet the shares sit at $19.74, well below the 200-day moving average of $23.82, near the $18.39 low since the last report and under the prior quarter's $20.30 floor. Optimism toward the commercial franchises appears to coexist with deep caution about the pipeline. Lower R&D guidance of $355 million to $380 million should help margins, but the departure of the R&D head by year-end adds to uncertainty about what comes next.

The central question is whether ACADIA's commercial base can carry the investment case regardless of how the pipeline story develops. If Nuplazid shows that the sales-force expansion is starting to pay off and Daybue keeps pace with its raised outlook, the case for at least the guidance midpoint strengthens and the stock's slide looks overdone on operating grounds. If Nuplazid stalls again, the raised outlook will look more fragile than it did in August.

This earnings preview was originally published on Earnings Whispers.

This article is for informational purposes only and is not investment advice. Earnings Whispers and its staff may hold positions in the securities mentioned. It is AI-assisted, based on proprietary Earnings Whispers data and company reports, and edited by Earnings Whispers staff.